Oncological outcomes of visibly complete transurethral resection prior to neoadjuvant chemotherapy for bladder cancer
Bryce Baird1, Ahmet Bilgili1, Augustus Anderson2
1Department of Urology Mayo Clinic, Jacksonville, FL, USA.
Purpose:
To evaluate the potential oncologic benefit of a visibly complete transurethral resection of a bladder tumor (TURBT) prior to neoadjuvant chemotherapy (NAC) and radical cystectomy (RC).
Materials And Methods:
We identified patients who received NAC and RC between 2011-2021. Records were reviewed to assess TURBT completeness. The primary outcome was pathologic downstaging (
Results:
We identified 153 patients, including 116 (76%) with a complete TURBT. Sixty-four (42%) achieved
Conclusions:
A visibly complete TURBT was not associated with pathologic downstaging, cancer-specific or recurrence-free survival following NAC and RC. These data do not support the need for repeat TURBT to achieve a visibly complete resection if NAC and RC are planned.
